Mon, 20 Feb 2017
Our Gold-rated large-blend funds range from focused to super diversified passive funds.
Morningstar's Heather Brilliant explains why investors should care about movement in market and sector correlations.
Growing corporate cash balances and slowing organic-growth opportunities could lead to increased deal volume this year even if economic uncertainty throttles some activity, says Morningstar's Bridget Freas.
Although the two office-supplies companies could realize meaningful cost synergies, the combined firm would still face enormous competitive pressures, says Morningstar's Liang Feng.
Five stats from the market and the stories behind them. This week: Fed's $40 billion bond buys in question, Wal-Mart's worrisome 1% same-store sales growth, and more.
Morningstar's Gaston Ceron addresses the short- and long-term prospects for and opportunities in ICE's takeover of NYSE Euronext.
Looking to fully fund an IRA for the 2012 tax year? Get a shortlist of ideas from Morningstar strategists Heather Brilliant , Russ Kinnel, Sam Lee, and Josh Peters.
Over the long run, cheap wide - moat stocks have handily outperformed the market, says Morningstar's Heather Brilliant .
Pharmacy benefit managers aren't household names, but recent consolidation in the industry is proving out the power of scale for these firms, says Morningstar's Matt Coffina.
The corporate bond market will probably struggle to return much above break-even in 2014.
While the sector looks fairly valued overall, we still see several stocks that offer attractive valuations across the different industries, including pharmacy benefit managers.
Widening investment-grade credit spreads and rising interest rates lead to losses.
Dec. 6-10, 2010.
©2017 Morningstar Advisor. All right reserved.